Kevin Fischbeck, an analyst from Bank of America Securities, reiterated the Buy rating on Cigna. The associated price target is $407.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kevin Fischbeck has given his Buy rating due to a combination of factors that indicate Cigna’s strong performance and potential for growth. The management’s reaffirmation of their long-term adjusted EPS growth target of 10-14% and their confidence in the 2025 outlook are key drivers of this positive assessment. Despite some elevated costs, the company’s medical loss ratio remains within expectations, and their strategic focus on margins over growth in certain segments is expected to yield favorable results.
Moreover, Cigna’s Evernorth segment continues to demonstrate impressive growth, with strong client retention in Pharmacy Benefit Management and significant expansion in Specialty Care Services. The recent multi-year contract extension with Prime Therapeutics and the consistent double-digit growth in their specialty distribution business further underscore the company’s robust operational performance. These elements collectively support the Buy rating, as Cigna appears well-positioned to navigate industry pressures and capitalize on future opportunities.
Fischbeck covers the Healthcare sector, focusing on stocks such as Centene, Cigna, and Elevance Health. According to TipRanks, Fischbeck has an average return of 3.4% and a 60.07% success rate on recommended stocks.
In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $390.00 price target.